Key result
Tricuspid TEER reduces TR to grade 2 or less in 70% of high-risk patients.
Why the study?
Severe tricuspid regurgitation carries high prevalence and adverse outcomes, but conventional surgical and pharmacological treatments remain limited, creating an unmet need to reduce morbidity and mortality.
This review summarizes the state of the art of transcatheter edge-to-edge repair for severe tricuspid regurgitation, focusing on patient selection, procedural aspects, and initial experiences in the Netherlands.
Supports early adoption in select high-risk cases; leaves open need for randomized trials on outcomes.
Despite the high prevalence and adverse clinical outcomes of severe tricuspid regurgitation (TR), conventional treatment options, surgical or pharmacological, are limited. Surgery is associated with a high peri-operative risk and medical treatment has not clearly resulted in clinical improvements. Therefore, there is a high unmet need to reduce morbidity and mortality in patients with severe TR. During recent years, several transcatheter solutions have been studied. This review focuses on the transcatheter edge-to-edge repair of TR (TTVR) with respect to patient selection, the procedure, pre- and peri-procedural echocardiographic assessments and clinical outcomes. Furthermore, we highlight the current status of TTVR in the Netherlands and provide data from our initial experience at the University Medical Centre Groningen.
No takes yet. Share an insight, caveat, or question.
Krikken et al. (2022) conducted a review in Severe tricuspid regurgitation (n=17). Transcatheter edge-to-edge tricuspid valve repair (MitraClip/TriClip) was evaluated on Reduction of tricuspid regurgitation to grade 2 or less. Transcatheter edge-to-edge tricuspid valve repair was feasible in high-risk patients and reduced tricuspid regurgitation to grade 2 or less in 70% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: